ICPV Study Day 22 July 2009
Wellcome Trust Brenner Building Leeds Institute of Molecular Medicine
Our first study day involved 23 participants and was immensely successful. The only complaint I heard was that there just wasn't enough time. There was a buzz of excited interaction between people affected by breast cancer, research nurses, scientists and clinicians. We are hugely grateful to Val Speirs and her team for hosting the day, to all the speakers for giving us their time. A brief account of the day follows with links to the presentations given. (See photos on left)
Val Speirs Reader in Cellular Pathology, LIMM/University of Leeds talked about the collection & use of tissue and its value to cell biology, in particular, the need for access to appropriate and annotated clinical material to make significant new progress in breast cancer research. This need was identified in the Breast Cancer Campaign Gap Analysis and has lead to the Breast Cancer Campaign Tissue Bank initiative. The mission statement for which is: To provide, in partnership with Campaign, highly specialised breast cancer related biomaterials to support cutting-edge translational research for the benefit of the patient
Debbie Holliday Research Fellow, LIMM/University of Leeds talked about the Development of laboratory models to study Breast Cancer. She has designed a 3 dimensional (3D) human model of breast cancer which includes the 3 major cell types involved in breast cancer: Tumour cells, Myoepithelial cells (protector cells) and Fibroblasts (tumour helper cells). These cells are grown in culture conditions which resemble those in the body ie grown in 3D rather than on a plastic Petri dish.
Laura Smith Research Fellow, LIMM/University of Leeds talked about using this 3D model to study radio-resistance in Breast Cancer. The main aim is to enable better patient selection for radiotherapy like the Oestrogen Receptor for Tamoxifen therapy and HER2 for Herceptin therapy. Nothing analogous is available to guide radiotherapy. The questions that can be asked using this 3D model are: Why do some cancers respond well to radiotherapy whilst others do not? What factors are involved? Testing radio-sensitizing drugs? Laura's study is particularly focusing on the effects of radiotherapy on Fibroblasts
Aidan Hindley GIFT Tissue Bank Nurse, University of Leeds/LTHT talked about the whole body bank called GIFT based at the University of Leeds - Making a GIFT for the future
Rob Coleman Professor & Honorary Consultant Medical Oncologist, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Talked about Breast Cancer and Bone Health: Normal Bone Health, Impact of Cancer Therapies on Bone Health, Therapeutic Strategies and Management Guidelines.
Raj Achuthan Consultant Breast and Oncoplastic Surgeon, Leeds General Infirmary talked about Different methods of breast reconstruction. He discussed the advantages and disadvantages of immediate versus delayed breast reconstruction and also the different types of reconstruction available.
Dave Ardron, Chair NCRI Consumer Liaison Group, spoke to us about the NCRI and welcomed the formation of our group. He said he wished he had a similar group to call upon for clinical trials in lung cancer.
Lucy Ziegler Research Fellow, St James's Institute of Oncology, University of Leeds consulted us on the measures of emotional distress she is developing with the COMPASS collaboration.
Steven Pollock & Michele Cummings then took us on a tour of the laboratories connected with the tissue bank. We saw some of the cells they use in their 3D model and also the digital imaging setup which was all very impressive
Click here for copies of presentations and reports
Warwick Clinical Trials
12 members of ICPV attended a residential Clinical Trials Course at the University of Warwick from 17th to 19th April 2018. The course was run by Professor Janet Dunn and covered the different types of studies undertaken; consent; trial design; statistics and bringing a drug to market. One of the highlights of the course was a visit to the West Midlands Surgical Training Centre where delegates had the privilege of seeing real body parts and having basic anatomy explained to them by the team. The delegates would like to thank Professor Janet Dunn for her outstanding enthusiasm and for her generous hospitality.
Open letter calling on Government to prioritise interests of cancer patients in Brexit negotiations
ICPV have come together with 18 other cancer charities to put our names to an open letter to Government. We want Government to prioritise seeking continued alignment with the EU drug licensing
process and Clinical Trials Regulation after Brexit. It is hoped this letter will be published in the national press in the near future.
See below to read.
2017 Summer School
The 2017 ICPV Summer School was held over two days in June at Stirling University. The theme of the event was Cancer Survivorship and Living Well Cancer. Click below for details of the course. More details.
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.